Teva launches generic Viagra in 9 countries; Valeant shares snapped up; Sandoz moves forward with Enbrel biosimilar;

Teva

 @FiercePharma: CX, that's 7 trials of 5 biosims for Novartis ... Novartis starts PhIII trial of biosimilar of Amgen's Enbrel. Report | Follow @FiercePharma

 @EricPFierce: Has down-home Paula become the 'Deen' of bad publicity for Novo Nordisk? Item | Follow @EricPFierce

 @CarlyHFierce: Shoutout to FierceBiotech in First Manhattan's letter to Vivus shareholders. Letter | Story | Follow @CarlyHFierce

Upcoming Webinar

Lifecycle Management Strategies Targeted For Patient Populations with Swallowing Disorders

Hear from industry experts as they discuss life cycle management strategies for patients with swallowing disorders and the overall impact on patient perception. The webinar will include several panel speakers representing different perspectives and case study examples. Save your spot and register today!

> Teva Pharmaceutical Industries ($TEVA) has hit the ground running with generic Viagra now that the Pfizer ($PFE) patent has fallen off, immediately launching it in Germany, the U.K., Italy, the Netherlands, Switzerland, Ireland, Austria, Belgium and Denmark. Story

> Novartis' ($NVS) generic unit Sandoz has launched a late-stage trial with its biosimilar version of Amgen's ($AMGN) Enbrel, even though Amgen in 2011 got a new patent that it says extends protection of the blockbuster until 2028. Story

> Boehringer Ingelheim has submitted an application to the European Medicines Agency (EMA) for the use of anticoagulant Pradaxa for the treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE. Report

> German Bayer says new data has affirmed the effectiveness of its anticoagulant Xarelto as single-drug therapy for treating pulmonary embolism and deep vein thrombosis. Item

> Underwriters have agreed to buy 3.53 million additional shares of Valeant Pharmaceuticals International ($VRX) at $85 a share, which Valeant intends to use to help pay for its buyout of eye-care company Bausch + Lomb. Announcement

> An Indian court has upheld a decision by the state government in Maharashtra to cancel Johnson & Johnson's ($JNJ) license to manufacture cosmetics from its facility in Mulund in northeast Mumbai, which the state revoked because the company in 2007 used an unapproved method of sterilizing some batches of baby powder without notifying the state FDA. Story

Medical Device News

 @FierceMedDev: Edwards wins Japanese nod for next-gen Sapien valve. Story | Follow @FierceMedDev

 @DamianFierce: Miss our ADA 2013 coverage? Diabetes news from Medtronic and J&J. | Follow @DamianFierce

 @MichaelGFierce: FDA approved Lombard's Aorflex delivery system, used with its Aorfix stent. Looking to launch this year. More | Follow @MichaelGFierce

> Medtronic leaps toward artificial pancreas with MiniMed study. Story

> J&J's Animas reveals positive artificial pancreas data. Article

Biotech News

 @FierceBiotech: Troubled AstraZeneca models a new industry R&D tie-up as setbacks mount. Story | Follow @FierceBiotech

 @JohnCFierce: Sandoz bulls ahead with full slate of PhIII biosimilar studies. News | Follow @JohnCFierce

 @RyanMFierce: PFE shares software for biotech drug research to pharma rivals like GSK, Roche and others. Story | Follow @RyanMFierce

 @EmilyMFierce:  Our special ADA 2013 issue, via @RyanMFierce | Follow @EmilyMFierce

> FDA clamps partial hold on Cell Therapeutics trial after patient dies. News

> KKR scoops up global CRO PRA in $1.3B buyout deal. More

> Sanofi chief threatens R&D cutbacks unless EMA retreats on open data plan. News

CRO News

> Icon, Clintec launch grad programs for clinical research. Article

> CRS signs on with Bayer for early trials. Story

> Novotech reaches into Hong Kong, Philippines. News

> inVentiv taps PatientsLikeMe for trial recruitment. Report

Biotech IT News

> Roche designs online software for sequencing business. Story

> FDA taps India's GVK for database support in drug recycling. More

> Pfizer shares software for biotech drug research with pharma rivals. News

> Scientists follow 'Facebook' strategy to corral cancer Big Data. Story

> PatientsLikeMe seals CRO deal for online trial recruitment. Article

And Finally... Development is quickly advancing for pills that work as digestible computers that can wirelessly email information about patients who swallow them. Story

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.